gip and glp-1 agonist Frontiers The Effects of Dual GLP-1/GIP

Description

35-39.9: 0.61, 0.41 to 0.91

It is imperative to deepen our comprehension of the intricate relationship between GLP-1 RAs and psychiatric outcomes, particularly given the substantial association between obesity and psychiatric diseases

S., Fukushima, Y., Lingvay, I., Macura, S., Sndergaard, A

46 Adverse Effects and Tolerability of GLP-1RAs in Clinical Practice Although the cardiovascular benefits of GLP-1RAs are significant, their use is commonly associated with well-characterised adverse effects that can affect tolerability and long-term medication adherence, as detailed below

For the groups randomized to placebo, 1.2 mg of pemvidutide, 1.8 mg, and 2.4 mg,, week-24 absolute reduction in liver volume, which is linked to overall mortality, was 3.3%, 12.6%, 19.1%, and 18.0%